IMG 004
Alternative Names: HMPL 727; IMG-004Latest Information Update: 27 Sep 2024
At a glance
- Originator HUTCHMED
- Developer Inmagene
- Class Small molecules
- Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Immunological disorders
- Discontinued Multiple sclerosis
Most Recent Events
- 03 Sep 2024 Discontinued - Phase-I for Multiple sclerosis in China (PO) (Inmagenebio pipeline, September 2024)
- 27 Jun 2024 Pharmacokinetics, pharmacodynamics and adverse event data from a phase I trial (In volunteers) released by Inmagene Biopharmaceuticals
- 02 May 2024 Inmagene completes a phase I trial in Healthy volunteers in USA (NCT05349097)